Chimeric Therapeutics (ASX:CHM) has announced promising early results from its ongoing Phase 1/2 clinical trial of CHM CDH17, a novel third-generation CAR-T therapy targeting gastrointestinal cancers. …
Latest Video
New Stories
-
'Patient-centric partnerships will unlock brighter and more equitable outcomes for all'
October 21, 2025 - - Latest News -
Vaccine confidence slips as Australians grow more concerned about access to healthcare
October 20, 2025 - - Latest News -
NZ's Pharmac proposes new rules to manage 'Options for Investment' list - make it shorter
October 20, 2025 - - Latest News -
Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies
October 20, 2025 - - Australian Biotech -
Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum
October 20, 2025 - - Australian Biotech -
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 - - Australian Biotech -
Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion
October 20, 2025 - - Latest News